FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:341-343 July 30, 1998 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Hecht, F. M. PubMed Citation

The addition of human immunodeficiency virus type 1 (HIV-1)–protease inhibitors to the armamentarium of antiretroviral drugs has dramatically improved the prognosis for HIV-infected persons.^1,2,3 Although these agents do not eradicate the virus,^4,5,6 they can provide long-term control of viral replication and substantially prolong disease-free survival, and they represent an important therapeutic advance. As has been the case throughout the brief history of the HIV epidemic, any progress invariably leads to new obstacles to be overcome; the introduction of highly active antiretroviral therapy is certainly no exception to this rule.

A number of sociologic, pharmacologic, immunologic, and virologic issues challenge the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Giuffre, A. C., Higgins, J., Buckheit, R. W. Jr., North, T. W. (2003). Susceptibilities of Simian Immunodeficiency Virus to Protease Inhibitors. Antimicrob. Agents Chemother. 47: 1756-1759 [Abstract] [Full Text]  
• DiClemente, R J, Wingood, G M, Del Rio, C, Crosby, R A (2002). Prevention interventions for HIV positive individuals. Sex. Transm. Infect. 78: 393-395 [Full Text]  
• Martin-Fernandez, J., Escobar-Rodriguez, I., Campo-Angora, M., Rubio-Garcia, R. (2001). Evaluation of Adherence to Highly Active Antiretroviral Therapy. Arch Intern Med 161: 2739-2740 [Full Text]  
• Servais, J., Lambert, C., Fontaine, E., Plesséria, J.-M., Robert, I., Arendt, V., Staub, T., Schneider, F., Hemmer, R., Burtonboy, G., Schmit, J.-C. (2001). Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor. Antimicrob. Agents Chemother. 45: 893-900 [Abstract] [Full Text]  
• Boden, D., Hurley, A., Zhang, L., Cao, Y., Guo, Y., Jones, E., Tsay, J., Ip, J., Farthing, C., Limoli, K., Parkin, N., Markowitz, M. (1999). HIV-1 Drug Resistance in Newly Infected Individuals. JAMA 282: 1135-1141 [Abstract] [Full Text]  
• Lucas, G. M., Chaisson, R. E., Moore, R. D. (1999). Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions. ANN INTERN MED 131: 81-87 [Abstract] [Full Text]  
• (1998). Transmission of Multiply Resistant HIV. AIDS Clin Care 1998: 3-3 [Full Text]